International Hepatology

How are PARP inhibitors, ARPIs, and radioligand therapy reshaping the treatment landscape for mCRPC? In this exclusive conversation, Professor Qiu Xuefeng and Dr. Darren Poon dive into the latest advancements in precision oncology, discussing key challenges, emerging therapies, and the impact of HRR and BRCA testing on treatment decisions.

Monogenic diseases, a class of hereditary disorders caused by gene mutations, are diverse and have a profound impact. In the pediatric field, stem cell transplantation is emerging as a promising treatment for conditions such as inborn errors of immunity (IEI), very early-onset inflammatory bowel disease (VEO-IBD), and inherited metabolic diseases (IEM). At the 12th Lu Daopei Hematology Forum, Hematology Frontier invited Dr. Xiaowen Zhai from the National Children's Medical Center and Children's Hospital of Fudan University to provide an in-depth analysis of the current state of stem cell transplantation for pediatric monogenic diseases in China and discuss future research directions to advance the field.

Published on February 18, 2025, in the Journal of Hepatology, the NuTide:121 study investigated NUC-1031/cisplatin as a first-line treatment for advanced biliary tract cancer (aBTC) compared to the gemcitabine/cisplatin standard…

Published on February 11, 2025, in Hepatology, this study sheds light on the persistent global burden of hepatitis B virus (HBV)-related liver cancer. While significant progress has been made in…

New research evaluates the effectiveness of abbreviated MRI (AMRI) compared to ultrasound in detecting early-stage hepatocellular carcinoma (HCC). Findings suggest that AMRI significantly outperforms ultrasound in sensitivity and specificity, particularly…

Liver cancer is the third leading cause of cancer-related deaths worldwide, with hepatocellular carcinoma (HCC) accounting for nearly 90% of primary liver cancers. The newly updated EASL Clinical Practice Guidelines…

A recent study published in Hepatology explores the role of SUMOylation in cholangiocarcinoma (CCA) and its potential as a therapeutic target. The research analyzed tumors from multiple patient cohorts and…

A recent phase IIb randomized trial, published in the Journal of Hepatology, evaluated Icosabutate, an oral FFAR1/FFAR4 agonist, in patients with biopsy-confirmed MASH and fibrosis (F1-F3). While the primary endpoint…

New research in JHEP Reports explores how Salsalate, a rheumatoid arthritis therapy, may enhance the effectiveness of Lenvatinib in treating MASH-driven hepatocellular carcinoma (HCC). By stimulating AMPK, enhancing fatty acid…